Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7755304 | 0.98 | KDM1A (0.45) | KDM1ASLC6A4SLC6A3SLC6A2MEN1 | |
| SCHEMBL11696762 | 0.80 | KDM1A (0.54) | KDM1AMEN1KMT2ASIGMAR1 | |
| SCHEMBL7378848 | 0.78 | SLC6A4 (0.46) | KDM1ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7546727 | 0.78 | SLC6A4 (0.46) | KDM1ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18228175 | 0.77 | KDM1A (0.38) | KDM1AMEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL7949501 | 0.77 | SLC6A4 (0.45) | KDM1ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16404981 | 0.77 | TRPV3 (0.40) | KDM1ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7984137 | 0.72 | KDM1A (0.50) | KDM1AMEN1KMT2A | |
| SCHEMBL7948379 | 0.72 | SLC6A4 (0.43) | KDM1ASLC6A4SLC6A3SLC6A2KMT2A | |
| SCHEMBL9545809 | 0.72 | SLC6A4 (0.43) | KDM1ASLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. | 2014-10-23 | — | — | US | disclosed |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008065177-A1 | PROCESSES FOR PREPARING DESMETHYLSERTRALINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CEREP (FR) | 2008-06-05 | — | — | WO | disclosed |
| EP-1904045-A1 | USE OF 4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTALEN-1-YLAMINE FOR TREATING CANCER | Anceris (FR) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904066-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | Sepracor Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006797-A1 | USE OF 4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTALEN-1-YLAMINE FOR TREATING CANCER | ANCERIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006003-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | SEPRACOR INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1157002-A1 | 1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051972-A1 | 1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
| EP-0341015-A2 | Improved process for preparing a ketimine | PFIZER INC. (US) | 1989-11-08 | — | — | EP | disclosed |
| EP-0295050-A1 | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | KDM1A 642/4885SLC6A4 38/4885SLC6A3 114/4885 |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | KDM1A 642/4885SLC6A4 38/4885SLC6A3 114/4885 |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | KDM1A 642/4885SLC6A4 38/4885SLC6A3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.